相关临床试验
259
15 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1981
进行中（未招募）
3
1.2%
已完成
129
49.8%
Enrolling By Invitation
1
0.4%
尚未招募
11
4.3%
招募中
35
13.5%
暂停
2
0.8%
Temporarily Not Available
1
0.4%
终止
3
1.2%
Unknown
70
27.0%
撤回
4
1.5%
暂无批准数据
- Gene Solutions has launched SPOT-MAS, an AI-powered multi-cancer early detection platform in Taiwan, integrating multi-omics cell-free DNA analysis to bridge gaps in traditional cancer screening. - The technology analyzes genetic, epigenetic, and fragmentomic features using AI algorithms to enhance early detection accuracy and predict tumor location more precisely than single biomarker approaches. - Taiwan medical experts emphasize the urgent clinical need, noting that early cancer detection can result in five-year survival rates several times higher than late-stage detection. - The launch represents a significant step toward making multi-cancer screening accessible beyond premium healthcare, with plans for cross-sector collaboration to establish comprehensive cancer prevention frameworks.
- Far Eastern Memorial Hospital in New Taipei City administered Taiwan's first dose of Kisunla (donanemab), a new Alzheimer's drug that targets underlying disease causes rather than just symptoms. - The monoclonal antibody treatment, developed by Eli Lilly, was given to an 83-year-old woman and represents a breakthrough approach to reducing amyloid plaques in the brain. - Both Kisunla and Leqembi require 12-18 months of treatment to significantly reduce amyloid accumulation, with fewer than 100,000 of Taiwan's 350,000 dementia patients eligible for these therapies. - While promising, experts caution these drugs are not cures and require ongoing monitoring, with long-term effectiveness and side effects still under evaluation.
